Annual Shareholders Equity
$67.09 M
+$287.73 M+130.41%
December 31, 2024
Summary
- As of February 20, 2025, ALNY annual stockholders equity is $67.09 million, with the most recent change of +$287.73 million (+130.41%) on December 31, 2024.
- During the last 3 years, ALNY annual shareholders equity has fallen by -$521.12 million (-88.59%).
- ALNY annual shareholders equity is now -96.20% below its all-time high of $1.77 billion, reached on December 31, 2017.
Performance
ALNY Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Quarterly Shareholders Equity
$67.09 M
+$34.73 M+107.36%
December 31, 2024
Summary
- As of February 20, 2025, ALNY quarterly stockholders equity is $67.09 million, with the most recent change of +$34.73 million (+107.36%) on December 31, 2024.
- Over the past year, ALNY quarterly shareholders equity has increased by +$287.73 million (+130.41%).
- ALNY quarterly shareholders equity is now -96.20% below its all-time high of $1.77 billion, reached on December 31, 2017.
Performance
ALNY Quarterly Shareholders Equity Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Highlights
High & Low
Earnings dates
Shareholders Equity Formula
Shareholders Equity = Total Assets − Total Liabilities
ALNY Shareholders Equity Trends
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | +130.4% | +130.4% |
| 3 y3 years | -88.6% | +130.4% |
| 5 y5 years | -95.3% | +130.4% |
ALNY Shareholders Equity Highs & Lows
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3-year | -88.6% | +130.4% | -88.6% | +116.4% |
| 5 y | 5-year | -95.3% | +130.4% | -95.3% | +116.4% |
| alltime | all time | -96.2% | +130.4% | -96.2% | +116.4% |
Alnylam Pharmaceuticals Shareholders Equity History
| Date | Annual | Quarterly |
|---|---|---|
| Dec 2024 | $67.09 M(-130.4%) | $67.09 M(+107.4%) |
| Sep 2024 | - | $32.35 M(-1154.9%) |
| Jun 2024 | - | -$3.07 M(-98.6%) |
| Mar 2024 | - | -$219.27 M(-0.6%) |
| Dec 2023 | -$220.64 M(+39.5%) | -$220.64 M(+33.0%) |
| Sep 2023 | - | -$165.87 M(-59.4%) |
| Jun 2023 | - | -$408.13 M(+57.4%) |
| Mar 2023 | - | -$259.24 M(+63.8%) |
| Dec 2022 | -$158.22 M(-126.9%) | -$158.22 M(+133.9%) |
| Sep 2022 | - | -$67.64 M(-138.4%) |
| Jun 2022 | - | $176.04 M(-56.1%) |
| Mar 2022 | - | $401.17 M(-31.8%) |
| Dec 2021 | $588.20 M(-42.1%) | $588.20 M(-22.2%) |
| Sep 2021 | - | $755.89 M(-11.4%) |
| Jun 2021 | - | $853.36 M(-7.9%) |
| Mar 2021 | - | $926.19 M(-8.9%) |
| Dec 2020 | $1.02 B(-29.4%) | $1.02 B(-16.4%) |
| Sep 2020 | - | $1.22 B(-13.2%) |
| Jun 2020 | - | $1.40 B(+3.7%) |
| Mar 2020 | - | $1.35 B(-6.2%) |
| Dec 2019 | $1.44 B(+10.5%) | $1.44 B(-10.5%) |
| Sep 2019 | - | $1.61 B(-8.5%) |
| Jun 2019 | - | $1.76 B(+13.6%) |
| Mar 2019 | - | $1.55 B(+18.8%) |
| Dec 2018 | $1.30 B(-26.3%) | $1.30 B(-11.9%) |
| Sep 2018 | - | $1.48 B(-8.8%) |
| Jun 2018 | - | $1.62 B(-7.6%) |
| Mar 2018 | - | $1.75 B(-0.7%) |
| Dec 2017 | $1.77 B(+92.0%) | $1.77 B(+66.8%) |
| Sep 2017 | - | $1.06 B(-5.7%) |
| Jun 2017 | - | $1.12 B(+35.2%) |
| Mar 2017 | - | $830.90 M(-9.7%) |
| Dec 2016 | $920.22 M(-27.2%) | $920.22 M(-9.3%) |
| Sep 2016 | - | $1.01 B(-7.6%) |
| Jun 2016 | - | $1.10 B(-7.6%) |
| Mar 2016 | - | $1.19 B(-6.0%) |
| Dec 2015 | $1.26 B(+35.1%) | $1.26 B(-4.3%) |
| Sep 2015 | - | $1.32 B(-6.2%) |
| Jun 2015 | - | $1.41 B(-5.9%) |
| Mar 2015 | - | $1.50 B(+59.8%) |
| Dec 2014 | $936.27 M | $936.27 M(+3.5%) |
| Sep 2014 | - | $904.48 M(-4.0%) |
| Jun 2014 | - | $942.27 M(-1.3%) |
| Date | Annual | Quarterly |
|---|---|---|
| Mar 2014 | - | $954.97 M(+253.2%) |
| Dec 2013 | $270.35 M(+101.7%) | $270.35 M(-9.2%) |
| Sep 2013 | - | $297.58 M(-3.4%) |
| Jun 2013 | - | $308.18 M(-1.1%) |
| Mar 2013 | - | $311.56 M(+132.4%) |
| Dec 2012 | $134.05 M(+13.6%) | $134.05 M(-24.3%) |
| Sep 2012 | - | $177.16 M(-5.9%) |
| Jun 2012 | - | $188.29 M(-4.6%) |
| Mar 2012 | - | $197.38 M(+67.3%) |
| Dec 2011 | $118.00 M(-25.4%) | $118.00 M(-7.7%) |
| Sep 2011 | - | $127.87 M(-6.4%) |
| Jun 2011 | - | $136.55 M(-6.2%) |
| Mar 2011 | - | $145.57 M(-8.0%) |
| Dec 2010 | $158.23 M(-11.1%) | $158.23 M(-1.5%) |
| Sep 2010 | - | $160.64 M(-2.9%) |
| Jun 2010 | - | $165.48 M(-3.7%) |
| Mar 2010 | - | $171.83 M(-3.4%) |
| Dec 2009 | $177.97 M(-12.0%) | $177.97 M(-2.2%) |
| Sep 2009 | - | $182.02 M(-1.3%) |
| Jun 2009 | - | $184.48 M(-7.2%) |
| Mar 2009 | - | $198.74 M(-1.7%) |
| Dec 2008 | $202.13 M(+1.5%) | $202.13 M(-1.2%) |
| Sep 2008 | - | $204.56 M(+2.7%) |
| Jun 2008 | - | $199.17 M(-1.8%) |
| Mar 2008 | - | $202.81 M(+1.8%) |
| Dec 2007 | $199.17 M(-1.0%) | $199.17 M(+3.2%) |
| Sep 2007 | - | $192.94 M(+7.6%) |
| Jun 2007 | - | $179.27 M(-5.7%) |
| Mar 2007 | - | $190.03 M(-5.5%) |
| Dec 2006 | $201.17 M(+225.6%) | $201.17 M(+92.0%) |
| Sep 2006 | - | $104.78 M(-4.8%) |
| Jun 2006 | - | $110.08 M(-6.6%) |
| Mar 2006 | - | $117.92 M(+90.9%) |
| Dec 2005 | $61.78 M(+33.9%) | $61.78 M(+167.8%) |
| Sep 2005 | - | $23.07 M(-21.5%) |
| Jun 2005 | - | $29.39 M(-26.2%) |
| Mar 2005 | - | $39.83 M(-13.7%) |
| Dec 2004 | $46.14 M(-272.8%) | $46.14 M(+2.6%) |
| Sep 2004 | - | $44.98 M(-11.2%) |
| Jun 2004 | - | $50.67 M(-229.7%) |
| Mar 2004 | - | -$39.08 M(+46.3%) |
| Dec 2003 | -$26.71 M(+474.8%) | -$26.71 M |
| Dec 2002 | -$4.65 M | - |
FAQ
- What is Alnylam Pharmaceuticals annual stockholders equity?
- What is the all time high annual shareholders equity for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals annual shareholders equity year-on-year change?
- What is Alnylam Pharmaceuticals quarterly stockholders equity?
- What is the all time high quarterly shareholders equity for Alnylam Pharmaceuticals?
- What is Alnylam Pharmaceuticals quarterly shareholders equity year-on-year change?
What is Alnylam Pharmaceuticals annual stockholders equity?
The current annual shareholders equity of ALNY is $67.09 M
What is the all time high annual shareholders equity for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high annual stockholders equity is $1.77 B
What is Alnylam Pharmaceuticals annual shareholders equity year-on-year change?
Over the past year, ALNY annual stockholders equity has changed by +$287.73 M (+130.41%)
What is Alnylam Pharmaceuticals quarterly stockholders equity?
The current quarterly shareholders equity of ALNY is $67.09 M
What is the all time high quarterly shareholders equity for Alnylam Pharmaceuticals?
Alnylam Pharmaceuticals all-time high quarterly stockholders equity is $1.77 B
What is Alnylam Pharmaceuticals quarterly shareholders equity year-on-year change?
Over the past year, ALNY quarterly stockholders equity has changed by +$287.73 M (+130.41%)